Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD30 Positive Primary Mediastinal Large B-cell Lymphoma”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Testing effectiveness (Phase 2)Study completedNCT02423291
What this trial is testing

SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL

Who this might be right for
Primary Mediastinal Large B Cell Lymphoma
Fondazione Italiana Linfomi - ETS 15
Testing effectiveness (Phase 2)WithdrawnNCT02623920
What this trial is testing

Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaMediastinal Large B-cell LymphomaGrey Zone Lymphoma+4 more
University of Arizona
Early research (Phase 1)Active Not RecruitingNCT04526834
What this trial is testing

Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

Who this might be right for
Anaplastic Large Cell LymphomaPeripheral T Cell LymphomaExtranodal NK/T-cell Lymphoma+2 more
Tessa Therapeutics 21
Testing effectiveness (Phase 2)Study completedNCT01994850
What this trial is testing

Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients

Who this might be right for
CD30 Positive Primary Mediastinal Large B-cell LymphomaCD30-Positive Diffuse Large B-Cell LymphomaCD30-Positive Gray Zone Lymphoma
Abramson Cancer Center at Penn Medicine 32